Kolkata: Alniche has announced to launch a new range of products – VIROBIND Mouth Spray and VIROBIND AB Capsules to address microbial infections, says a press release.
VIROBIND mouth spray is a scientifically tested enzyme-based formulation that kills 99.99% of germs. The spray can be used in the early stages of infection to recover and relieve sore throat, cough, rhinorrhoea, and other common cold symptoms.
VIROBIND AB (Veg. Capsule) is a probiotic formulation for the treatment of respiratory infections. Consumption of one capsule daily will help in the formation of beneficial bacteria (i.e., probiotics) that helps to bolster or recover effective immune function in the GI tract and also indirectly in the lung.
Girish Arora, Founder and Managing Director of Alniche Lifesciences said, “We as a specialty pharma company always focus on identifying, developing, and supplying a quality range of critical care medicines throughout the country in the shortest possible time to mitigate the suffering of patients.”
He said, “We provide complete therapy for Covid-19 patients with a product range that consists of supportive and immunity booster medicines. VIROBIND range is an addition to our portfolio.”
The Company said that there are various products in the pipeline that would be launched soon in various therapy areas. Effikasia is in active discussion with global companies for manufacturing global brands in India for India and emerging markets.